Introduction In a strategic move to accelerate the development and launch of genetic medicines, BridgeBio Pharma has successfully secured up to USD 1.25 billion from Blue Owl Capital and Canada Pension Plan Investment Board. The cornerstone of BridgeBio’s funding initiative involves a strategic agreement with Blue Owl Capital and Canada Pension Plan Investment Board. In